This newsletter is brought to you by DigestiveJobs.com — hire faster, get hired faster.
- Post-endoscopy EAC: most cases look preventable. Auckland registry review found 7.1% of esophageal adenocarcinomas occurred 6–36 months after a “negative” EGD; 71% were potentially avoidable (follow-up delays, inappropriate decisions, or inadequate exams). Takeaway: tighten Barrett’s surveillance workflows, biopsy protocols, and follow-up tracking. Read more →
- Cryoballoon ablation for Barrett’s neoplasia shows strong multicenter results. In 107 patients across 8 European centers, multifocal cryoballoon ablation achieved CE-BE 94% (ITT) with 13% stricture rate. Takeaway:in expert hands, FCBA is an effective EET option; weigh stricture risk, especially with shorter BE segments. Read more →
- AI-assisted colonoscopy: real-world impact under the microscope. New GIE Articles-in-Press study examines how CADe affects detection and miss-rates in practice. Takeaway: if you have CADe, ensure it’s turned on and track your ADR/AMR—early evidence suggests quality gains, but watch for over-reliance. Read more →
- Color-vision deficiency: IEE can level the playing field. Prospective work shows image-enhanced endoscopy improves lesion visibility for endoscopists with color-vision deficiency. Takeaway: standardize IEE settings and consider tailored filters to reduce miss risk across your team. Read more →
- “Leaky gut” test concept: indigo carmine permeability spray. Pilot study explores endoscopic IC spray with serum detection as a mucosal permeability assay; UC patients had higher serum IC vs controls. Takeaway:intriguing, but experimental—don’t change practice yet; watch for validation and safety data. Read more →
- LLMs in GI show sociodemographic bias signals. Quality-improvement study in JAMA Network Open (Sep 24) found LLM recommendations varied by demographics—especially around mental-health referrals. Takeaway: if you’re piloting AI triage or scribe tools, add bias monitoring and human oversight. Read more →
- HBV letter & reply sharpen “inactive carrier” risk stratification. Gut correspondence (Sep 27) underscores that qHBsAg <100 IU/mL identifies low-risk inactive CHB; authors debate surveillance and treatment thresholds. Takeaway: consider qHBsAg in hepatology clinics to personalize HCC surveillance intensity. Reply → PubMed →
- Device milestone: first fully robotic endoluminal procedure by a gastroenterologist. In the PARADIGM IDE trial, EndoQuest’s Endoluminal Surgical System enabled a gastroenterologist to complete a fully robotic flexible endoluminal case. Takeaway: robotic-flex platforms are edging toward therapeutic GI—track trial sites and training needs. Read more →
- Heads-up for authors: ESGE’s WISE 2026 abstract submissions just opened (Sept 30). Takeaway: if you’ve got quality/innovation projects, submit early. Read more →
Brought to you by DigestiveJobs.com.
